NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Receives $8.50 Average Target Price from Brokerages

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) has been assigned a consensus rating of “Moderate Buy” from the five brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $8.50.

Several research firms have recently weighed in on NRSN. D. Boral Capital reissued a “buy” rating and set a $14.00 target price on shares of NeuroSense Therapeutics in a research report on Wednesday, April 8th. Roth Mkm started coverage on NeuroSense Therapeutics in a research report on Tuesday, March 10th. They issued a “buy” rating and a $3.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NeuroSense Therapeutics in a research report on Friday, May 8th.

Hedge Funds Weigh In On NeuroSense Therapeutics

Several hedge funds have recently bought and sold shares of the business. Yorkville Advisors Global LP bought a new position in NeuroSense Therapeutics in the 4th quarter valued at $77,000. Squarepoint Ops LLC lifted its holdings in shares of NeuroSense Therapeutics by 91.0% in the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after buying an additional 45,450 shares during the period. Jane Street Group LLC purchased a new stake in shares of NeuroSense Therapeutics in the 2nd quarter worth $54,000. Finally, Two Sigma Investments LP purchased a new stake in shares of NeuroSense Therapeutics in the 3rd quarter worth $26,000. Institutional investors own 1.04% of the company’s stock.

NeuroSense Therapeutics Price Performance

NASDAQ:NRSN opened at $0.82 on Friday. The company has a market cap of $26.74 million, a price-to-earnings ratio of -1.52 and a beta of 1.60. The stock’s 50 day simple moving average is $0.78 and its two-hundred day simple moving average is $0.89. NeuroSense Therapeutics has a 1 year low of $0.63 and a 1 year high of $2.60.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.